- Home
- EONR vs ALZN Comparison
EONR vs ALZN Comparison
Compare EONR & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- ALZN
- Stock Information
- Founded
- EONR 2020
- ALZN 2016
- Country
- EONR United States
- ALZN United States
- Employees
- EONR N/A
- ALZN N/A
- Industry
- EONR
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- EONR
- ALZN Health Care
- Exchange
- EONR NYSE
- ALZN Nasdaq
- Market Cap
- EONR 6.1M
- ALZN 6.9M
- IPO Year
- EONR N/A
- ALZN 2021
- Fundamental
- Price
- EONR $1.33
- ALZN $1.64
- Analyst Decision
- EONR
- ALZN
- Analyst Count
- EONR 0
- ALZN 0
- Target Price
- EONR N/A
- ALZN N/A
- AVG Volume (30 Days)
- EONR 5.1M
- ALZN 361.1K
- Earning Date
- EONR 11-15-2024
- ALZN 12-13-2024
- Dividend Yield
- EONR N/A
- ALZN N/A
- EPS Growth
- EONR N/A
- ALZN N/A
- EPS
- EONR N/A
- ALZN N/A
- Revenue
- EONR $22,964,891.00
- ALZN N/A
- Revenue This Year
- EONR N/A
- ALZN N/A
- Revenue Next Year
- EONR N/A
- ALZN N/A
- P/E Ratio
- EONR N/A
- ALZN N/A
- Revenue Growth
- EONR N/A
- ALZN N/A
- 52 Week Low
- EONR $0.81
- ALZN $1.40
- 52 Week High
- EONR $13.93
- ALZN $33.00
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- ALZN 40.84
- Support Level
- EONR N/A
- ALZN $1.58
- Resistance Level
- EONR N/A
- ALZN $1.90
- Average True Range (ATR)
- EONR 0.00
- ALZN 0.14
- MACD
- EONR 0.00
- ALZN 0.05
- Stochastic Oscillator
- EONR 0.00
- ALZN 39.53
About EONR EON RESOURCES INC
HNR Acquisition Corp is a blank check company.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.